WHO Guideline Recommendations for Alternatives to Lithium in Bipolar I Disorder

First‑Line Alternative: Valproate

• Valproate (divalproex) should be offered as the first alternative when lithium cannot be used, and is recommended alongside lithium in WHO guidelines for the treatment of acute bipolar mania and for long‑term maintenance – applicable to adults with Bipolar I disorder who are lithium‑intolerant or have contraindications. 1

Maintenance Duration After Stabilization

• WHO guidelines advise that maintenance pharmacotherapy be continued for at least 2 years after the most recent bipolar episode to reduce risk of relapse in patients with Bipolar I disorder. 2

Alternatives in Resource‑Limited Settings

• When availability or cost restrict the use of second‑generation antipsychotics, WHO guidelines identify haloperidol as a standard option for acute mania in low‑resource environments. 1

Third‑Line Option: Carbamazepine

• Carbamazepine is recommended by WHO guidelines as an alternative mood stabilizer for acute bipolar mania when lithium is unsuitable, acknowledging that its evidence base is less robust than that of valproate. 2

Antidepressant Use Guidance

• WHO guidance cautions against antidepressant monotherapy; antidepressants should always be combined with a mood stabilizer—valproate is preferred when lithium cannot be used—to prevent mood destabilization in Bipolar I patients. 1

Treatment Algorithm Summary (WHO‑Based)

• The WHO‑endorsed treatment algorithm places valproate as the first‑choice agent for both acute antimanic control and maintenance therapy in lithium‑intolerant Bipolar I patients. 2

Psychoeducation Recommendation

• WHO guidelines recommend routine psychoeducation alongside any pharmacologic regimen to improve treatment adherence and clinical outcomes in Bipolar I disorder. 1

Maintenance Treatment and Monitoring in Bipolar I Disorder

First‑Line Maintenance Medications

• Lithium is FDA‑approved for maintenance therapy in bipolar disorder and is considered a first‑line agent for preventing both manic and depressive episodes; it remains the preferred long‑term mood stabilizer for adults with bipolar I disorder【3】【4】.
• Lamotrigine is FDA‑approved for maintenance therapy in adults with bipolar disorder and offers particular protection against depressive recurrence, making it a valuable complement to lithium’s antimanic effect【3】【4】.

Monitoring During Medication Taper

• During a gradual reduction of quetiapine XR, mood stability should be assessed weekly and then bi‑weekly for three months after discontinuation to detect early signs of relapse【4】.
• Therapeutic lithium serum concentrations should be maintained with regular laboratory monitoring, typically every three to six months once stable【3】.

Monitoring, Maintenance, and Patient Education for Mood Stabilizer Therapy

Laboratory Monitoring Requirements

• Lithium therapy requires baseline and ongoing laboratory monitoring every 3–6 months, including complete blood count, thyroid function, urinalysis, blood urea nitrogen, creatinine, and serum calcium. 5
• When prescribing atypical antipsychotics (e.g., quetiapine) as an alternative mood stabilizer, clinicians should obtain baseline measurements of body‑mass index, waist circumference, blood pressure, fasting glucose, and fasting lipid panel, and then monitor body‑mass index monthly for the first 3 months and quarterly thereafter. 5

Duration of Maintenance Therapy

• Evidence indicates that the medication regimen that stabilizes acute mania should be continued for 12–24 months, with some patients requiring lifelong therapy. 5

Guidelines for Discontinuation

• Discontinuation of prophylactic mood‑stabilizing medication should be performed gradually, with close monitoring for relapse during the taper. 5

Patient and Family Education

• Patients and families should receive thorough education about early signs and symptoms of mood episodes so that therapy can be promptly reinstated if needed. 5